Articles publicats

Cerca col·leccions:

Ordena'ls per:	Mostrar els resultats:	Format de visualizació:

Articles publicats	2 registres trobats	La cerca s'ha fet en 0.00 segons.

12 p, 1.2 MB

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease / Startin, Carla M. (LonDownS Consortium (London Down Syndrome Consortium)) ; Ashton, Nicholas J. (University of Gothenburg) ; Hamburg, Sarah (LonDownS Consortium (London Down Syndrome Consortium)) ; Hithersay, Rosalyn (LonDownS Consortium (London Down Syndrome Consortium)) ; Wiseman, Frances K. (University College London) ; Mok, Kin Y. (Hong Kong University of Science and Technology) ; Hardy, John (University College London) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Lovestone, Simon (University of Oxford) ; Parnetti, Lucilla (University of Perugia) ; Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ; Hye, Abdul (Maudsley NHS Foundation) ; Fisher, Elisabeth ; Nizetic, Dean ; Tybulewicz, Victor ; Karmiloff-Smith, Anette ; Al-Janabi, Tamara ; Zhang, David ; Strydom, André (LonDownS Consortium (London Down Syndrome Consortium)) ; Universitat Autònoma de Barcelona
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. [...]
2019 - DOI (Digital Object Identifier)

10.1186/s13195-019-0477-0
Alzheimer's research & therapy, Vol. 11 Núm. 1 (21 2019) , p. 26

Registre complet -

9 p, 1012.4 KB

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : A cross-sectional analysis from the AB255 Study / Pérez-Grijalba, Virginia (Araclon Biotech S.L.) ; Arbizu, Javier (Clínica Universidad de Navarra) ; Romero, Judith (Araclon Biotech S.L.) ; Prieto, Elena (Clínica Universidad de Navarra) ; Pesini, Pedro (Araclon Biotech S.L.) ; Sarasa, Leticia (Araclon Biotech S.L.) ; Guillen, Fernando (Clínica Universidad de Navarra) ; Monleón, Inmaculada (Araclon Biotech S.L.) ; San-José, Itziar (Araclon Biotech S.L.) ; Martínez-Lage, Pablo (Fundación CITA-Alzheimer) ; Munuera, Josep (Institut de Recerca Sant Joan de Déu) ; Hernández, Isabel (Instituto de Salud Carlos III) ; Buendía, Mar (Universitat Internacional de Catalunya) ; Sotolongo-Grau, Oscar (Universitat Internacional de Catalunya) ; Alegret, Montserrat (Instituto de Salud Carlos III) ; Ruiz, Agustín (Instituto de Salud Carlos III) ; Tárraga, Lluís (Instituto de Salud Carlos III) ; Boada, Mercè (Instituto de Salud Carlos III) ; Sarasa, Manuel (Araclon Biotech S.L.) ; Goñi Imízcoz, Miguel (Hospital Divino Vallés (Burgos)) ; Pujadas, Francesc ; Villarejo, Alberto ; Frank, Ana ; Peña-Casanova, Jordi ; Fernández, Manuel ; Piñol, Gerard ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Gil, Pedro ; Pascual, Luis F. ; Aguilar Barberà, Miquel ; Frisoni, Giovanni B. ; Matias-Guiu, Jorge ; Andreasen, Niels ; Antúnez, Carmen ; Universitat Autònoma de Barcelona
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. [...]
2019 - DOI (Digital Object Identifier)

10.1186/s13195-019-0549-1
Alzheimer's research & therapy, Vol. 11 Núm. 1 (january 2019) , p. 96

Registre complet -

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.